Menu Search
Equities

Krka dd Novo Mesto

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0HLK:LSE

Krka dd Novo Mesto

Actions
  • Price (EUR)64.80
  • Today's Change0.00 / 0.00%
  • Shares traded174.00
  • 1 Year change0.00%
  • Beta1.0744
Data delayed at least 20 minutes, as of Feb 05 2026 15:07 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Krka dd Novo Mesto is a Slovenia-based company engaged in the production of pharmaceutical preparations. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services consisting of Spa resorts in Smarjeske Toplice, Dolenjske Toplice, Strunjan, Novo Mesto and Otocec. Krka dd Novo Mesto is a controlling company of the Krka Group that includes two subsidiaries in Slovenia, Terme Krka doo and Farma GRS doo, and over 20 subsidiaries abroad in such countries as Croatia, Germany, Sweden, Poland, Spain, United States, Ireland, among others.

  • Revenue in EUR (TTM)2.01bn
  • Net income in EUR398.80m
  • Incorporated1989
  • Employees13.11k
  • Location
    Krka dd Novo MestoSmarjeska cesta 6NOVO MESTO 8501SloveniaSVN
  • Phone+386 73312111
  • Fax+386 73321537
  • Websitehttps://www.krka.si/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.